---
title: "Sanmina surges 8%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305346574.md"
description: "Sanmina rose 8.05% to US$172.07. Up 32.13% over five sessions and up 14.66% YTD."
datetime: "2026-11-12T16:08:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305346574.md)
  - [en](https://longbridge.com/en/news/305346574.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305346574.md)
generator: "portal-rs"
---

# Sanmina surges 8%

Sanmina (SANM.US) surged more than **8%** during regular trading to **$172.07**.

The stock is up 32.13% over the past five sessions and up 14.66% year to date. It sits 45.70% above its 52-week low of US$118.10. Volume was 2.16 times its average and the intraday swing reached 12.56%.

The Nasdaq Composite is up 4.97% over the past five sessions and up 9.82% year to date.

The electronic equipment and instruments industry index rose 1.5% over the same period.

The company reported fiscal 2026 fourth-quarter non-GAAP earnings of $4.43 per share, topping the analyst consensus by $1.16. Revenue rose about 84% year-over-year to $3.858 billion, exceeding expectations by $380 million.

Sanmina guided to fiscal 2027 revenue of $17.5 billion to $19.5 billion, projecting sales growth of about 23% in subsequent quarters driven by cloud and AI systems as well as AI server manufacturing following the ZT Systems acquisition.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [SANM.US](https://longbridge.com/en/quote/SANM.US.md)

## Related News & Research

- [Sanmina grants director Shanker Trivedi 618 restricted stock units vesting quarterly](https://longbridge.com/en/news/305870940.md)
- [3 Supply Chain Stocks With AI Hardware Exposure Investors Should Watch](https://longbridge.com/en/news/305636444.md)
- [Sanmina (SANM) Stock May Still Look Like A Bargain After AI Guidance](https://longbridge.com/en/news/305135947.md)
- [AI Payroll Rollout Could Be A Game Changer For Workday (WDAY)](https://longbridge.com/en/news/306350754.md)
- [CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness](https://longbridge.com/en/news/306366333.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**